Vanguard Group Inc. Acquires 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Vanguard Group Inc. boosted its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 4,161.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,610,651 shares of the company’s stock after acquiring an additional 1,572,853 shares during the period. Vanguard Group Inc. owned 4.60% of Oruka Therapeutics worth $31,231,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AlphaCentric Advisors LLC bought a new position in Oruka Therapeutics during the 4th quarter worth approximately $119,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Oruka Therapeutics during the fourth quarter worth $144,000. Geode Capital Management LLC acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at $343,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Oruka Therapeutics in the 4th quarter valued at $303,000. Finally, Wellington Management Group LLP bought a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at $2,013,000. Institutional investors own 56.44% of the company’s stock.

Insider Transactions at Oruka Therapeutics

In related news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were bought at an average price of $11.44 per share, for a total transaction of $1,015,803.36. Following the purchase, the insider now directly owns 4,148,428 shares in the company, valued at approximately $47,458,016.32. This trade represents a 2.19 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired a total of 98,339 shares of company stock worth $1,128,456 in the last three months. Insiders own 22.67% of the company’s stock.

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $8.14 on Tuesday. The stock has a market capitalization of $304.77 million, a price-to-earnings ratio of -1.30 and a beta of 0.47. Oruka Therapeutics, Inc. has a 52 week low of $5.49 and a 52 week high of $31.13. The stock’s 50 day moving average price is $10.37 and its two-hundred day moving average price is $17.70.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Thursday, March 6th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.19. On average, equities research analysts forecast that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ORKA shares. Wolfe Research initiated coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price on the stock. Wedbush reiterated an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a report on Friday, March 7th. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Oruka Therapeutics has a consensus rating of “Buy” and an average target price of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.